Telix Pharmaceuticals Says First Part Of Phase Three Study Confirms Safety Profile, Biodistribution, Dosimetry Of Drug Candidate, Shares Jump 7%

MT Newswires Live

Mar 10

Telix Pharmaceuticals (ASX:TLX) said the first part of its ProstACT Global phase three study achieved its primary objectives, confirming the safety profile, biodistribution, and dosimetry of the drug candidate TLX591-Tx, or lutetium-177 rosopatamab tetraxetan in combination with one of three standard of care therapies, abiraterone, enzalutamide, or docetaxel, according to a Tuesday Australian bourse filing.

The tolerability profile was supported by dosimetry and low-grade non-hematologic events; the lesion dosimetry indicated no difference in absorbed dose profile across groups, and no adverse drug-drug interactions were observed in TLX591-Tx combinations.

The patient population consisted of patients with prostate-specific membrane antigen-positive metastatic castration resistant prostate cancer. ProstACT Global is a differentiated phase 3 trial comparing PSMA-targeted lutetium-177 rosopatamab tetraxetan therapy administered with standard-of-care compared with standard-of-care alone.

Its shares jumped 7% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2618607397"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618607397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618607397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 11:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618607397","market":"sg","top_or_hot":-1,"title":"Telix Pharmaceuticals Says First Part Of Phase Three Study Confirms Safety Profile, Biodistribution, Dosimetry Of Drug Candidate, Shares Jump 7%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) said the first part of its ProstACT Global phase three study achieved its primary objectives, confirming the safety profile, biodistribution, and dosimetry of the drug candidate TLX591-Tx, or lutetium-177 rosopatamab tetraxetan in combination with one of three standard of care therapies, abiraterone, enzalutamide, or docetaxel, according to a Tuesday Australian bourse filing.</p><p>The tolerability profile was supported by dosimetry and low-grade non-hematologic events; the lesion dosimetry indicated no difference in absorbed dose profile across groups, and no adverse drug-drug interactions were observed in TLX591-Tx combinations.</p><p>The patient population consisted of patients with prostate-specific membrane antigen-positive metastatic castration resistant prostate cancer. ProstACT Global is a differentiated phase 3 trial comparing PSMA-targeted lutetium-177 rosopatamab tetraxetan therapy administered with standard-of-care compared with standard-of-care alone.</p><p>Its shares jumped 7% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Pharmaceuticals Says First Part Of Phase Three Study Confirms Safety Profile, Biodistribution, Dosimetry Of Drug Candidate, Shares Jump 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Pharmaceuticals Says First Part Of Phase Three Study Confirms Safety Profile, Biodistribution, Dosimetry Of Drug Candidate, Shares Jump 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-10 11:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) said the first part of its ProstACT Global phase three study achieved its primary objectives, confirming the safety profile, biodistribution, and dosimetry of the drug candidate TLX591-Tx, or lutetium-177 rosopatamab tetraxetan in combination with one of three standard of care therapies, abiraterone, enzalutamide, or docetaxel, according to a Tuesday Australian bourse filing.</p><p>The tolerability profile was supported by dosimetry and low-grade non-hematologic events; the lesion dosimetry indicated no difference in absorbed dose profile across groups, and no adverse drug-drug interactions were observed in TLX591-Tx combinations.</p><p>The patient population consisted of patients with prostate-specific membrane antigen-positive metastatic castration resistant prostate cancer. ProstACT Global is a differentiated phase 3 trial comparing PSMA-targeted lutetium-177 rosopatamab tetraxetan therapy administered with standard-of-care compared with standard-of-care alone.</p><p>Its shares jumped 7% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618607397","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618607397","pubTimestamp":1773112015,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals  said the first part of its ProstACT Global phase three study achieved its primary objectives, confirming the safety profile, biodistribution, and dosimetry of the drug candidate TLX591-Tx, or lutetium-177 rosopatamab tetraxetan in combination with one of three standard of care therapies, abiraterone, enzalutamide, or docetaxel, according to a Tuesday Australian bourse filing.The tolerability profile was supported by dosimetry and low-grade non-hematologic events; the lesion dosimetry indicated no difference in absorbed dose profile across groups, and no adverse drug-drug interactions were observed in TLX591-Tx combinations.The patient population consisted of patients with prostate-specific membrane antigen-positive metastatic castration resistant prostate cancer. ProstACT Global is a differentiated phase 3 trial comparing PSMA-targeted lutetium-177 rosopatamab tetraxetan therapy administered with standard-of-care compared with standard-of-care alone.Its shares ju","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK4139":"生物科技","TLX.AU":"TELIX PHARMACEUTICALS LTD","TLX":"Telix Pharmaceuticals Ltd. (Uplisting)"},"translate_title":"Telix Pharmaceuticals表示，第三阶段研究的第一部分证实了候选药物的安全性、生物分布、剂量测定，股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1,"TLX":1.5},"content_text":"Telix Pharmaceuticals (ASX:TLX) said the first part of its ProstACT Global phase three study achieved its primary objectives, confirming the safety profile, biodistribution, and dosimetry of the drug candidate TLX591-Tx, or lutetium-177 rosopatamab tetraxetan in combination with one of three standard of care therapies, abiraterone, enzalutamide, or docetaxel, according to a Tuesday Australian bourse filing.The tolerability profile was supported by dosimetry and low-grade non-hematologic events; the lesion dosimetry indicated no difference in absorbed dose profile across groups, and no adverse drug-drug interactions were observed in TLX591-Tx combinations.The patient population consisted of patients with prostate-specific membrane antigen-positive metastatic castration resistant prostate cancer. ProstACT Global is a differentiated phase 3 trial comparing PSMA-targeted lutetium-177 rosopatamab tetraxetan therapy administered with standard-of-care compared with standard-of-care alone.Its shares jumped 7% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}